Medline (NASDAQ:MDLN) Stock Has Average Price Target of $46.08

Shares of Medline (NASDAQ:MDLN – Get Free Report) have earned an average rating of “Moderate Buy” from the twenty-nine analysts that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and twenty-three have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $46.08.

A number of equities research analysts have recently issued reports on the stock. Zacks Research downgraded shares of Medline from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. BTIG Research reaffirmed a “buy” rating and issued a $55.00 target price on shares of Medline in a report on Thursday, November 5th. Robert W. Baird set a $42.00 target price on Medline in a research report on Thursday, August 6th. Truist Financial cut their price target on Medline from $56.00 to $47.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Finally, Wells Fargo & Company cut their price target on Medline from $45.00 to $34.00 and set an “equal weight” rating for the company in a report on Tuesday, August 11th.

Get Our Latest Stock Report on MDLN

Insider Activity at Medline

In other news, major shareholder Private Ltd Gic sold 2,570,999 shares of Medline stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $35.35, for a total transaction of $90,884,814.65. Following the transaction, the insider directly owned 20,231,483 shares of the company’s stock, valued at $715,182,924.05. The trade was a 11.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 6,348,676 shares of company stock valued at $224,525,137 over the last 90 days. 0.81% of the stock is owned by company insiders.

Institutional Investors Weigh In On Medline

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its holdings in Medline by 68.3% in the 2nd quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock worth $25,000 after buying an additional 254 shares during the period. Whipplewood Advisors LLC purchased a new stake in Medline in the 1st quarter worth $30,000. Reyes Financial Architecture Inc. bought a new stake in Medline during the third quarter valued at about $30,000. NewEdge Advisors LLC raised its holdings in Medline by 100.0% during the second quarter. NewEdge Advisors LLC now owns 950 shares of the company’s stock valued at $37,000 after acquiring an additional 475 shares during the period. Finally, Allworth Financial LP raised its holdings in Medline by 86.2% during the second quarter. Allworth Financial LP now owns 1,052 shares of the company’s stock valued at $41,000 after acquiring an additional 487 shares during the period.

Medline Stock Performance

NASDAQ MDLN traded down $0.51 during trading hours on Friday, hitting $39.47. 8,433,866 shares of the company’s stock traded hands, compared to its average volume of 10,899,395. The business’s fifty day moving average price is $35.28 and its two-hundred day moving average price is $39.37. The company has a current ratio of 4.04, a quick ratio of 2.51 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $51.89 billion and a P/E ratio of 89.71. Medline has a 52 week low of $31.37 and a 52 week high of $50.88.

Medline (NASDAQ:MDLN – Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.32 by $0.12. Medline had a net margin of 1.84% and a return on equity of 8.21%. The business had revenue of $7.86 billion during the quarter. Equities research analysts predict that Medline will post 1.58 EPS for the current year.

Medline Company Profile

(Get Free Report)

Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations. The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations. Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.

Featured Stories

Analyst Recommendations for Medline (NASDAQ:MDLN)

Receive News & Ratings for Medline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medline and related companies with MarketBeat.com's FREE daily email newsletter.